Rebeca Franco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebeca Franco has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Nina A. Bickell
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY
12 shared publications - Natalia Egorova
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, United States
5 shared publications Ann Scheck McAlearney
Department of Family Medicine, The Ohio State University, Columbus, OH
4 shared publications- Jenny J. Lin
Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
4 shared publications - Kezhen Fei
Icahn School of Medicine at Mount Sinai, New York, NY
3 shared publications Alexandra Moss
Department of Family Medicine, The Ohio State University, Columbus, OH
2 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , e21675
Does oncologist productivity impact goals of care discussions?
E21675 Background: Oncologists are pressed to care for higher volumes of advanced cancer patients. Interviews with oncologists revealed their concern that goals of care (GoC) discussions take time. We studied the impact of oncologistsâ productivity on their conduct of meaningful GOC discussions with patients. Methods: At academic, municipal and rural hospitals, we recruited & randomized solid tumor oncologists & their newly diagnosed advanced cancer patients with
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , e21675
Does oncologist productivity impact goals of care discussions?
E21675 Background: Oncologists are pressed to care for higher volumes of advanced cancer patients. Interviews with oncologists revealed their concern that goals of care (GoC) discussions take time. We studied the impact of oncologistsâ productivity on their conduct of meaningful GOC discussions with patients. Methods: At academic, municipal and rural hospitals, we recruited & randomized solid tumor oncologists & their newly diagnosed advanced cancer patients with
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 6541
Thirty-day readmissions in metastatic cancer patients: Room for improvement?
6541 Background: To date, cancer has been excused from most readmission reduction efforts. Yet reported readmission rates for cancer patients discharged from medical services are as high as 27%. Some readmissions for patients with metastatic disease may be avoidable. We assessed the prevalence of potentially preventable readmissions and associated factors in adult patients with metastatic cancer. Methods: We measured 30 day readmissions for dehydration, cancer-related pain, and failure to thrive in patients with primary diagnosis metastatic cancer on index admission to a New York State hospital between December 1, 2012 and December 31, 2014. We used competing risk models to assess the effects of demographics, comorbidities, hospital type, payor, and discharge disposition. Results: During the study period, 11,275 patients had 19,307 index hospitalizations with primary diagnosis, metastatic cancer. The 30 day readmission rate was 24.5% of which 8.9% (424) were potentially preventable. Black (HR 1.26, 1.17-1.35) and Hispanic patients (HR 1.19, 1.09-1.31) had higher rates of readmission than whites. Being older (HR per 10 years of age 0.94, 0.90-0.97), female (HR 0.95, 0.91-0.99), having private insurance (HR 0.87, 0.87-0.81) and discharge to hospice (HR 0.62, 0.42-0.91) decreased risk of readmission. Discharge home with services (HR 1.21, 1.14-1.27) or to a skilled nursing facility (SNF) (HR 1.11, 1.01-1.23) conferred higher risk than going home unaided. Index hospitalization at public hospitals increased risk (HR 1.1, 1.02-1.18); teaching hospitals were protective (HR 0.84, 0.774-0.92). Patients with potentially preventable readmissions were younger (HR per 10 years of age 0.85, 0.78-0.93). Compared to those who went home unaided, patients discharged with services were more likely (HR 1.31, 1.05-1.64) and those discharged to SNF were less likely to have avoidable returns (HR 0.55, 0.37-0.81). Payor, gender, race, comorbidities, and index hospital type did not contribute. Conclusions: While the overall rate of potentially preventable admissions among metastatic cancer patients is low, higher readmission rates among those discharged home with help suggests that services supplied are not sufficient to address their health needs.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 6541
Thirty-day readmissions in metastatic cancer patients: Room for improvement?
6541 Background: To date, cancer has been excused from most readmission reduction efforts. Yet reported readmission rates for cancer patients discharged from medical services are as high as 27%. Some readmissions for patients with metastatic disease may be avoidable. We assessed the prevalence of potentially preventable readmissions and associated factors in adult patients with metastatic cancer. Methods: We measured 30 day readmissions for dehydration, cancer-related pain, and failure to thrive in patients with primary diagnosis metastatic cancer on index admission to a New York State hospital between December 1, 2012 and December 31, 2014. We used competing risk models to assess the effects of demographics, comorbidities, hospital type, payor, and discharge disposition. Results: During the study period, 11,275 patients had 19,307 index hospitalizations with primary diagnosis, metastatic cancer. The 30 day readmission rate was 24.5% of which 8.9% (424) were potentially preventable. Black (HR 1.26, 1.17-1.35) and Hispanic patients (HR 1.19, 1.09-1.31) had higher rates of readmission than whites. Being older (HR per 10 years of age 0.94, 0.90-0.97), female (HR 0.95, 0.91-0.99), having private insurance (HR 0.87, 0.87-0.81) and discharge to hospice (HR 0.62, 0.42-0.91) decreased risk of readmission. Discharge home with services (HR 1.21, 1.14-1.27) or to a skilled nursing facility (SNF) (HR 1.11, 1.01-1.23) conferred higher risk than going home unaided. Index hospitalization at public hospitals increased risk (HR 1.1, 1.02-1.18); teaching hospitals were protective (HR 0.84, 0.774-0.92). Patients with potentially preventable readmissions were younger (HR per 10 years of age 0.85, 0.78-0.93). Compared to those who went home unaided, patients discharged with services were more likely (HR 1.31, 1.05-1.64) and those discharged to SNF were less likely to have avoidable returns (HR 0.55, 0.37-0.81). Payor, gender, race, comorbidities, and index hospital type did not contribute. Conclusions: While the overall rate of potentially preventable admissions among metastatic cancer patients is low, higher readmission rates among those discharged home with help suggests that services supplied are not sufficient to address their health needs.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 6586
Does coaching goals of care discussion skills make a difference?
6586 Background: Advanced cancer patients often have a poor understanding of their cancer prognosis. Goals of Care (GoC) discussions provide information about the cancer, its treatment & prognosis and elicit patient values. Little is known about the best ways to enhance patient understanding, clarify values and move GoC discussions earlier in the disease process. We report the effect of coaching oncologists on GoC discussions. Methods: We recruited oncologists & their advanced cancer patients with < 2 year prognosis to a RCT testing a coaching model communication skills training. Patients were surveyed after their post-imaging visit. We define GoC discussions as patient report that their doctor talked about their cancer prognosis and clarified things most important to them given their disease. Outcome variables assess the impact of GoC on patientsâ knowledge on what to expect and clarity of values. Results: We enrolled 22/25 (88%) oncologists and 70% of eligible patients of whom 96 (55%) completed a survey. On average, doctors were 44 yrs old (32-66) and in practice 14.5 yrs (5-40). Patientsâ mean age was 62 yrs (20-95), 40% females, 58% white, 24% Latino & 22 % black. Overall, 2/3 of patients reported their treatmentâs goal was to cure their cancer; 14% reported cure to be unlikely. Patients felt more knowledgeable (79% vs 21%; p = 0.02) when their doctors discussed treatments, side effects & quality of life. When patients were asked about things important to them, they report being a bit clearer about their values (65% vs 35%; p = 0.16). Compared to controls, intervention patients felt more knowledgeable (78% v 63%; p = 0.17) but did not feel clearer about their values (60% v 54%; p = 0.59). Multivariate modeling found that poor health literacy (OR = 0.2; 95%CI: 0.07-0.82), having a GoC discussion (OR = 10.2; 1.7-63.1) and being in the intervention group (OR = 8.8; 1.4-55.2) significantly affected knowledge (model c = 0.88; p < 0.01). However, discussing whatâs important to patients did not help patients feel clearer about their values (OR = 2.7; 0.6-12.2; model c = 0.82; p < 0.05). Conclusions: Using a coaching model to teach oncologists communication skills may improve patientsâ understanding of what to expect with their cancer but does not impact their clarity of values. Clinical trial information: NCT02374255.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , 6586
Does coaching goals of care discussion skills make a difference?
6586 Background: Advanced cancer patients often have a poor understanding of their cancer prognosis. Goals of Care (GoC) discussions provide information about the cancer, its treatment & prognosis and elicit patient values. Little is known about the best ways to enhance patient understanding, clarify values and move GoC discussions earlier in the disease process. We report the effect of coaching oncologists on GoC discussions. Methods: We recruited oncologists & their advanced cancer patients with < 2 year prognosis to a RCT testing a coaching model communication skills training. Patients were surveyed after their post-imaging visit. We define GoC discussions as patient report that their doctor talked about their cancer prognosis and clarified things most important to them given their disease. Outcome variables assess the impact of GoC on patientsâ knowledge on what to expect and clarity of values. Results: We enrolled 22/25 (88%) oncologists and 70% of eligible patients of whom 96 (55%) completed a survey. On average, doctors were 44 yrs old (32-66) and in practice 14.5 yrs (5-40). Patientsâ mean age was 62 yrs (20-95), 40% females, 58% white, 24% Latino & 22 % black. Overall, 2/3 of patients reported their treatmentâs goal was to cure their cancer; 14% reported cure to be unlikely. Patients felt more knowledgeable (79% vs 21%; p = 0.02) when their doctors discussed treatments, side effects & quality of life. When patients were asked about things important to them, they report being a bit clearer about their values (65% vs 35%; p = 0.16). Compared to controls, intervention patients felt more knowledgeable (78% v 63%; p = 0.17) but did not feel clearer about their values (60% v 54%; p = 0.59). Multivariate modeling found that poor health literacy (OR = 0.2; 95%CI: 0.07-0.82), having a GoC discussion (OR = 10.2; 1.7-63.1) and being in the intervention group (OR = 8.8; 1.4-55.2) significantly affected knowledge (model c = 0.88; p < 0.01). However, discussing whatâs important to patients did not help patients feel clearer about their values (OR = 2.7; 0.6-12.2; model c = 0.82; p < 0.05). Conclusions: Using a coaching model to teach oncologists communication skills may improve patientsâ understanding of what to expect with their cancer but does not impact their clarity of values. Clinical trial information: NCT02374255.
- 10 March 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (8_suppl) , 107
Can a web-based tracking and feedback tool improve breast cancer care at safety-net hospitals?
107 Background: System failures, a cause of underuse in which doctors order care, patients donât refuse but care doesnât ensue, tend to happen more at safety net hospitals (SNH). Tracking & follow-up approaches that close referral loops in SNHs may reduce underuse. In a randomized trial, we tested a Tracking & Feedback (T&F) tool to reduce underuse of adjuvant breast cancer treatment. Methods: We recruited 5 community & 5 municipal SNHs that serve a large proportion of minorities in the NYC metropolitan area. We implemented rapid case ascertainment, a T&F tool and trained point persons at each site to determine if women with newly operated stage 1-3 breast cancer, connected with the oncologist since such connections are associated with getting treated. The tool created a daily âto doâ reminder for point persons to ascertain if patients were seen by the oncologist. Point persons then relayed this information to surgeons to follow through as they deemed necessary. Underuse includes: no RT after lumpectomy or mastectomy with > 4 positive nodes; no chemo for HR- and no hormonal therapy for HR+ tumors > 1cm; no trastuzumab for Her2+ tumors. We interviewed key informants about tool usefulness. We conducted intention to treat and pre-post analyses to assess tool and implementation effectiveness, respectively. Results: Pre-intervention, despite randomizing hospitals, intervention (INT) hospitals had fewer whites (4% vs 14%; p = 0.0005), poorer follow-up approaches (0.68 vs 0.80; p = 0.07), less Medicaid & uninsured patients (36% vs 62%; p < .0001) and more underuse (28% vs 15%; p = 0.002) compared to control (CNTL) hospitals; comorbidities and stage were similar. The RCT found no difference in underuse rates (9% at INT & 11% at CNTL hospitals; p = 0.8). Because randomization did not result in equivalent distributions, we modeled pre- (N = 403) and post (N = 191) populations controlling for time period and clustering & found that hospitals with better follow-up (OR = 0.82; 95% CI: 0.71-0.96) had less underuse. In settings with poor follow-up & tracking approaches, key informants found the tool useful. Conclusions: While the RCT findings were negative, they suggest a T&F tool may help reduce underuse in SNHs with poor follow-up capabilities. Clinical trial information: NCT01544374.
- 10 March 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (8_suppl) , 107
Can a web-based tracking and feedback tool improve breast cancer care at safety-net hospitals?
107 Background: System failures, a cause of underuse in which doctors order care, patients donât refuse but care doesnât ensue, tend to happen more at safety net hospitals (SNH). Tracking & follow-up approaches that close referral loops in SNHs may reduce underuse. In a randomized trial, we tested a Tracking & Feedback (T&F) tool to reduce underuse of adjuvant breast cancer treatment. Methods: We recruited 5 community & 5 municipal SNHs that serve a large proportion of minorities in the NYC metropolitan area. We implemented rapid case ascertainment, a T&F tool and trained point persons at each site to determine if women with newly operated stage 1-3 breast cancer, connected with the oncologist since such connections are associated with getting treated. The tool created a daily âto doâ reminder for point persons to ascertain if patients were seen by the oncologist. Point persons then relayed this information to surgeons to follow through as they deemed necessary. Underuse includes: no RT after lumpectomy or mastectomy with > 4 positive nodes; no chemo for HR- and no hormonal therapy for HR+ tumors > 1cm; no trastuzumab for Her2+ tumors. We interviewed key informants about tool usefulness. We conducted intention to treat and pre-post analyses to assess tool and implementation effectiveness, respectively. Results: Pre-intervention, despite randomizing hospitals, intervention (INT) hospitals had fewer whites (4% vs 14%; p = 0.0005), poorer follow-up approaches (0.68 vs 0.80; p = 0.07), less Medicaid & uninsured patients (36% vs 62%; p < .0001) and more underuse (28% vs 15%; p = 0.002) compared to control (CNTL) hospitals; comorbidities and stage were similar. The RCT found no difference in underuse rates (9% at INT & 11% at CNTL hospitals; p = 0.8). Because randomization did not result in equivalent distributions, we modeled pre- (N = 403) and post (N = 191) populations controlling for time period and clustering & found that hospitals with better follow-up (OR = 0.82; 95% CI: 0.71-0.96) had less underuse. In settings with poor follow-up & tracking approaches, key informants found the tool useful. Conclusions: While the RCT findings were negative, they suggest a T&F tool may help reduce underuse in SNHs with poor follow-up capabilities. Clinical trial information: NCT01544374.
- Open Access
- 1 November 2016
- Published by Ubiquity Press, Ltd. in eGEMs (Generating Evidence & Methods to improve patient outcomes)
- Vol. 4  (1) , 22
A Validation Study of Administrative Claims Data to Measure Ovarian Cancer Recurrence and Secondary Debulking Surgery
Administrative claims data offer an alternative to chart abstraction to assess ovarian cancer recurrence, treatment and outcomes. Such analyses have been hindered by lack of valid recurrence and treatment algorithms. In this study, we sought to develop claims-based algorithms to identify ovarian cancer recurrence and secondary debulking surgery, and to validate them against the gold-standard of chart abstraction. We conducted chart validation studies; 2 recurrence algorithms and 1 secondary surgery among 94 ovarian cancer patients treated at one hospital between 2003-2009. A new recurrence algorithm was based on treatment timing (âĽ6 months after primary treatment) and a previously validated algorithm was based on secondary malignancy codes. A secondary debulking surgery algorithm was based on surgical billing codes. The new recurrence algorithm had: sensitivity=100% (95% confidence interval [CI]=87%-=100%), specificity=89% (95%CI=78%-95%), kappa=84% (SE=10%) while the secondary-malignancy-=code recurrence algorithm had: sensitivity=84% (95%CI=66%-94%), specificity=44% (95%CI=31%-=57%), kappa=23% (SE=8%). The secondary surgery algorithm had: sensitivity=77% (95%CI=50%-92%), = specificity= 92% (95%CI=83%-97%), kappa=66% (SE=10%).=. A recurrence algorithm based on treatment timing accurately identified ovarian cancer =recurrence. If validated in other populations, such an algorithm can provide a tool to compare effectiveness of recurrent ovarian cancer treatments.
- 1 November 2016
- Published by Ubiquity Press, Ltd. in eGEMs (Generating Evidence & Methods to improve patient outcomes)
- Vol. 4  (1) , 22
Open AccessA Validation Study of Administrative Claims Data to Measure Ovarian Cancer Recurrence and Secondary Debulking Surgery
Administrative claims data offer an alternative to chart abstraction to assess ovarian cancer recurrence, treatment and outcomes. Such analyses have been hindered by lack of valid recurrence and treatment algorithms. In this study, we sought to develop claims-based algorithms to identify ovarian cancer recurrence and secondary debulking surgery, and to validate them against the gold-standard of chart abstraction. We conducted chart validation studies; 2 recurrence algorithms and 1 secondary surgery among 94 ovarian cancer patients treated at one hospital between 2003-2009. A new recurrence algorithm was based on treatment timing (âĽ6 months after primary treatment) and a previously validated algorithm was based on secondary malignancy codes. A secondary debulking surgery algorithm was based on surgical billing codes. The new recurrence algorithm had: sensitivity=100% (95% confidence interval [CI]=87%-=100%), specificity=89% (95%CI=78%-95%), kappa=84% (SE=10%) while the secondary-malignancy-=code recurrence algorithm had: sensitivity=84% (95%CI=66%-94%), specificity=44% (95%CI=31%-=57%), kappa=23% (SE=8%). The secondary surgery algorithm had: sensitivity=77% (95%CI=50%-92%), = specificity= 92% (95%CI=83%-97%), kappa=66% (SE=10%).=. A recurrence algorithm based on treatment timing accurately identified ovarian cancer =recurrence. If validated in other populations, such an algorithm can provide a tool to compare effectiveness of recurrent ovarian cancer treatments.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , 1568
Are racial differences in obesity and insulin resistance related to aggressive breast cancer?
1568 Background: Black women are more likely to die of breast cancer and have more aggressive type cancers than white women. Black women are also more likely to have obesity and insulin resistance than white women. Insulin resistance has been associated with faster tumor growth in mouse models of breast cancer, but has not been studied as a potential mediator of racial disparities in women with breast cancer. We hypothesized that black women would have more aggressive breast cancer at presentation and this would be associated with obesity and insulin resistance. Methods: We recruited 281 (80% white, 20% black) women with a new primary breast cancer and measured pre-operative fasting blood glucose and insulin, BMI, waist circumference (WC), Nottingham prognostic index (NPI). We classified aggressive breast cancer as a NPI > 4.4. We calculated HOMA-IR (HOMA) scores and classified insulin resistance a HOMA > 2.8, the upper quartile of insulin resistance in the US population. Patients self-identified race. Results: Of 281 women with new breast cancer, average age was 58 years (SD = 12.5). 181 (64%) were stage I; 89 (32%) stage II; 11 (4%) stage III at time of diagnosis. Seventeen percent of cancers had an NPI > 4.4. There was no racial difference in stage or aggressive breast cancer: 22% of blacks vs. 16% of whites (p = 0.3) had cancers with NPI > 4.4. Eight percent of women were insulin resistant: 11% blacks vs. 7% whites (p = 0.4). There were also racial differences in BMI (32.3 in B vs. 26.0 in W; p < .0001), WC (110cm in B vs 94cm in W, p < 0.001), HOMA score (1.7 in B vs.1.2 vs W; p = 0.002), NPI score (4.0 in B vs. 3.6 in W, p = 0.01) and triple negative breast cancer (15% in B vs 6% in W, p = 0.04). HOMA score was positively associated with NPI score (r = 0.18; p = 0.02). HOMA_IR partially mediates the effect of black race with more aggressive cancer (β = 0.07; 95%CI: 0.02-0.15). Conclusions: Among women with newly diagnosed breast cancer, insulin resistance partially mediates the relationship between black race with more aggressive cancer suggesting that hyperinsulinemia may promote breast cancer progression and contribute to racial disparities in breast cancer survival.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , 1568
Are racial differences in obesity and insulin resistance related to aggressive breast cancer?
1568 Background: Black women are more likely to die of breast cancer and have more aggressive type cancers than white women. Black women are also more likely to have obesity and insulin resistance than white women. Insulin resistance has been associated with faster tumor growth in mouse models of breast cancer, but has not been studied as a potential mediator of racial disparities in women with breast cancer. We hypothesized that black women would have more aggressive breast cancer at presentation and this would be associated with obesity and insulin resistance. Methods: We recruited 281 (80% white, 20% black) women with a new primary breast cancer and measured pre-operative fasting blood glucose and insulin, BMI, waist circumference (WC), Nottingham prognostic index (NPI). We classified aggressive breast cancer as a NPI > 4.4. We calculated HOMA-IR (HOMA) scores and classified insulin resistance a HOMA > 2.8, the upper quartile of insulin resistance in the US population. Patients self-identified race. Results: Of 281 women with new breast cancer, average age was 58 years (SD = 12.5). 181 (64%) were stage I; 89 (32%) stage II; 11 (4%) stage III at time of diagnosis. Seventeen percent of cancers had an NPI > 4.4. There was no racial difference in stage or aggressive breast cancer: 22% of blacks vs. 16% of whites (p = 0.3) had cancers with NPI > 4.4. Eight percent of women were insulin resistant: 11% blacks vs. 7% whites (p = 0.4). There were also racial differences in BMI (32.3 in B vs. 26.0 in W; p < .0001), WC (110cm in B vs 94cm in W, p < 0.001), HOMA score (1.7 in B vs.1.2 vs W; p = 0.002), NPI score (4.0 in B vs. 3.6 in W, p = 0.01) and triple negative breast cancer (15% in B vs 6% in W, p = 0.04). HOMA score was positively associated with NPI score (r = 0.18; p = 0.02). HOMA_IR partially mediates the effect of black race with more aggressive cancer (β = 0.07; 95%CI: 0.02-0.15). Conclusions: Among women with newly diagnosed breast cancer, insulin resistance partially mediates the relationship between black race with more aggressive cancer suggesting that hyperinsulinemia may promote breast cancer progression and contribute to racial disparities in breast cancer survival.
- 1 March 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (7_suppl) , 186
Patient and clinician perspectives on treatment decision-making for African American men with prostate cancer.
186 Background: Prostate cancer is the most common cancer for men in the US, yet the burden of this disease falls disproportionately on African Americans (AAs). The disparityâs etiology is complex. Surgery and radiotherapy offer similar survival but historically have different rates of performance with younger and white men more likely to undergo surgery and AAs more likely to experience underuse. This study aims to examine treatment decision-making (TDM) processes for AA men from patient and physician perspectives. Methods: At 1 academic and 1 municipal urban hospital, pathology records and a tumor registry from 2007-2012 were used to identify 359 AA and 282 white men with locally advanced prostate cancer, a Gleason score of 7-10, and receipt of definitive treatment. 15/17 treating physicians of participating patients were interviewed. Underuse overall was 4%, AA had higher rate of underuse compared to whites (6% vs. 1% respectively, p = 0.0002). 14 patients with longer times between diagnosis and treatment were recruited for 4 focus groups & 2 interviews lasting 60-90 minutes eliciting perspectives on themes related to TDM. Transcripts were coded and analyzed using a grounded theory approach. Results: Preliminary analysis of patient interviews suggests that patients primarily base their treatment decisions on physician recommendations. Patients were often unaware of treatment side effects. However, some patients felt this deficit helped them decide to receive treatment, whereas if they had known about possible impotence and incontinence, they would have refused treatment. Physicians recognized that patient concerns about side effects were a critical TDM factor. Physicians attributed prolonged delays between diagnosis and treatment to waiting times for tests of possible tumor spread and medical comorbidities. Conclusions: Understanding decision making and care processes for AA men with local advanced prostate cancer is critical to reducing the treatment and outcome disparities in this population. This study identifies several patient and physician/system factors that contribute to this process. These data can help inform interventions to improve prostate cancer care for AA men.
- 1 March 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (7_suppl) , 186
Patient and clinician perspectives on treatment decision-making for African American men with prostate cancer.
186 Background: Prostate cancer is the most common cancer for men in the US, yet the burden of this disease falls disproportionately on African Americans (AAs). The disparityâs etiology is complex. Surgery and radiotherapy offer similar survival but historically have different rates of performance with younger and white men more likely to undergo surgery and AAs more likely to experience underuse. This study aims to examine treatment decision-making (TDM) processes for AA men from patient and physician perspectives. Methods: At 1 academic and 1 municipal urban hospital, pathology records and a tumor registry from 2007-2012 were used to identify 359 AA and 282 white men with locally advanced prostate cancer, a Gleason score of 7-10, and receipt of definitive treatment. 15/17 treating physicians of participating patients were interviewed. Underuse overall was 4%, AA had higher rate of underuse compared to whites (6% vs. 1% respectively, p = 0.0002). 14 patients with longer times between diagnosis and treatment were recruited for 4 focus groups & 2 interviews lasting 60-90 minutes eliciting perspectives on themes related to TDM. Transcripts were coded and analyzed using a grounded theory approach. Results: Preliminary analysis of patient interviews suggests that patients primarily base their treatment decisions on physician recommendations. Patients were often unaware of treatment side effects. However, some patients felt this deficit helped them decide to receive treatment, whereas if they had known about possible impotence and incontinence, they would have refused treatment. Physicians recognized that patient concerns about side effects were a critical TDM factor. Physicians attributed prolonged delays between diagnosis and treatment to waiting times for tests of possible tumor spread and medical comorbidities. Conclusions: Understanding decision making and care processes for AA men with local advanced prostate cancer is critical to reducing the treatment and outcome disparities in this population. This study identifies several patient and physician/system factors that contribute to this process. These data can help inform interventions to improve prostate cancer care for AA men.
- 19 February 2016
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 32  (7) , 745-753
Metabolic syndrome and preâdiabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways
Background: Women with obesity and type 2 diabetes (T2D) are at greater risk of dying from breast cancer than women without these conditions. Obesity and T2D are associated with insulin resistance and endogenous hyperinsulinemia and are more common in Black women. There is increasing disparity in breast cancer mortality between Black and White women in the USA. We hypothesize that insulin resistance and endogenous hyperinsulinemia in Black women with breast cancer contribute to their greater breast cancer mortality and are associated with increased insulin receptor signalling in tumours.Methods: We will recruit 350 Black women and 936 White women with newly diagnosed breast cancer. We will determine the presence or absence of the metabolic syndrome/preâdiabetes and insulin resistance by measuring body mass index, waist circumference, lipids, blood pressure, glucose, insulinâlike growth factor binding protein 1 and insulin. Breast cancer prognosis will be determined by a Nottingham Prognostic Index (NPI), with poor prognosis being defined as NPI >4.4. Tumour insulin receptor signalling will be determined by immunohistochemistry. Insulin receptor subtype expression will be measured using Nanostring. Analysis of these factors will determine whether endogenous hyperinsulinemia is associated with a worse prognosis in Black women than White women and increased tumour insulin receptor signalling.Conclusions: The results of this study will determine if the metabolic syndrome and preâdiabetes contribute to racial disparities in breast cancer mortality. It may provide the basis for targeting systemic insulin resistance and/or tumour insulin receptor signalling to reduce racial disparities in breast cancer mortality. Copyright Š 2016 John Wiley & Sons, Ltd.
- 19 February 2016
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 32  (7) , 745-753
Metabolic syndrome and preâdiabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways
Background: Women with obesity and type 2 diabetes (T2D) are at greater risk of dying from breast cancer than women without these conditions. Obesity and T2D are associated with insulin resistance and endogenous hyperinsulinemia and are more common in Black women. There is increasing disparity in breast cancer mortality between Black and White women in the USA. We hypothesize that insulin resistance and endogenous hyperinsulinemia in Black women with breast cancer contribute to their greater breast cancer mortality and are associated with increased insulin receptor signalling in tumours.Methods: We will recruit 350 Black women and 936 White women with newly diagnosed breast cancer. We will determine the presence or absence of the metabolic syndrome/preâdiabetes and insulin resistance by measuring body mass index, waist circumference, lipids, blood pressure, glucose, insulinâlike growth factor binding protein 1 and insulin. Breast cancer prognosis will be determined by a Nottingham Prognostic Index (NPI), with poor prognosis being defined as NPI >4.4. Tumour insulin receptor signalling will be determined by immunohistochemistry. Insulin receptor subtype expression will be measured using Nanostring. Analysis of these factors will determine whether endogenous hyperinsulinemia is associated with a worse prognosis in Black women than White women and increased tumour insulin receptor signalling.Conclusions: The results of this study will determine if the metabolic syndrome and preâdiabetes contribute to racial disparities in breast cancer mortality. It may provide the basis for targeting systemic insulin resistance and/or tumour insulin receptor signalling to reduce racial disparities in breast cancer mortality. Copyright Š 2016 John Wiley & Sons, Ltd.
- 20 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (3_suppl) , 28
Breast cancer: Does where you get treated affect survival?
28 Background: Under the ACA, more women are insured with Medicaid which should improve access to cancer care. However, Disproportionate Share Hospitals (DSH) are due to receive reduced subsidies thereby threatening resource stressed facilities and poorer hospitals are experiencing greater financial penalties due to higher readmission rates. In NYS, 83% of Medicaid breast cancer patients got their cancer surgery at DSH hospitals. As women gain more choice and access, they will require information about hospitalsâ quality and outcomes of cancer care. We sought to determine whether there are survival advantages among breast cancer patients treated at hospitals with varying proportions of Medicaid patients. Methods: We used non-obstetric delivery Medicaid discharges from NYS hospitals in 2005-13 to create quintiles of hospitalized patients with Medicaid. Women treated for breast cancer were identified with a diagnostic and procedure code for breast cancer. Based on NYS hospital discharge database linked with vital statistics death records, we calculated hazard ratios using marginal Cox model with a robust sandwich variance estimator controlling for clustering of patients within the hospital, age and comorbidity. Results: Quintiles of Medicaid hospitals ranged from low (0-15%), to low medium (15-22%), medium (22-29%), medium-high (29-50%), to high ( > 50%). 26% of breast cancer patients were treated at the low; 22% at the low medium; 20% at the medium; 21% at the medium-high and 11% at high quintile hospitals. Patients treated in hospitals with > 50% Medicaid patients had a higher long-term mortality (HR = 1.51; 95%CI: 1.19-1.93) compared to those treated at the lowest quintile hospitals. Sensitivity analyses to adjust for stage are underway. Conclusions: While the ACA may improve access to breast cancer treatment, the long term impact on survival remains questionable as women with breast cancer treated at hospitals with high proportions of Medicaid patients may have worse survival. Analyses to control for stage are underway. Pending these results, hospitals with high proportions of Medicaid patients may need to target cancer quality improvement efforts to assure equitable outcomes.
- 20 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (3_suppl) , 28
Breast cancer: Does where you get treated affect survival?
28 Background: Under the ACA, more women are insured with Medicaid which should improve access to cancer care. However, Disproportionate Share Hospitals (DSH) are due to receive reduced subsidies thereby threatening resource stressed facilities and poorer hospitals are experiencing greater financial penalties due to higher readmission rates. In NYS, 83% of Medicaid breast cancer patients got their cancer surgery at DSH hospitals. As women gain more choice and access, they will require information about hospitalsâ quality and outcomes of cancer care. We sought to determine whether there are survival advantages among breast cancer patients treated at hospitals with varying proportions of Medicaid patients. Methods: We used non-obstetric delivery Medicaid discharges from NYS hospitals in 2005-13 to create quintiles of hospitalized patients with Medicaid. Women treated for breast cancer were identified with a diagnostic and procedure code for breast cancer. Based on NYS hospital discharge database linked with vital statistics death records, we calculated hazard ratios using marginal Cox model with a robust sandwich variance estimator controlling for clustering of patients within the hospital, age and comorbidity. Results: Quintiles of Medicaid hospitals ranged from low (0-15%), to low medium (15-22%), medium (22-29%), medium-high (29-50%), to high ( > 50%). 26% of breast cancer patients were treated at the low; 22% at the low medium; 20% at the medium; 21% at the medium-high and 11% at high quintile hospitals. Patients treated in hospitals with > 50% Medicaid patients had a higher long-term mortality (HR = 1.51; 95%CI: 1.19-1.93) compared to those treated at the lowest quintile hospitals. Sensitivity analyses to adjust for stage are underway. Conclusions: While the ACA may improve access to breast cancer treatment, the long term impact on survival remains questionable as women with breast cancer treated at hospitals with high proportions of Medicaid patients may have worse survival. Analyses to control for stage are underway. Pending these results, hospitals with high proportions of Medicaid patients may need to target cancer quality improvement efforts to assure equitable outcomes.
- 20 October 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32  (30) , 243
What fixes can improve cancer care quality at safety-net hospitals?
243 Background: Safety-net hospitals are at higher risk of poor quality cancer care and vary in levels of quality performance. Types of quality problems may differ and require different interventions. We undertook this study to identify organizational factors affecting quality and assess the early findings of the innovationâs impact on hand-offs between specialists. Methods: As part of a RCT testing a web-based tracking and feedback innovation to close referral loops, new breast cancer cases are rapidly ascertained, and post-surgical medical and radiation oncologist visits are assessed. Surgeons are alerted to patients who do not show to oncology visits to stimulate action. Of 153 enrolled women (98 Intervention/ 55 Control), 4% are white. In addition, we conducted 90 key informant interviews in 9 safety-net hospitals in the NYC metropolitan area and performed a qualitative comparative analysis (QCA), a method to assess causal complexity, to identify organizational factors associated with poor quality. Results: No-shows at oncology appointments triggering surgeon feedback occurred for 5/98 (5%) new breast cancer patients. QCA revealed 6 conditions associated with poor quality-defined as underuse of needed adjuvant treatment: information sharing; follow-up; system support; patient-centered culture; flexibility and private practice. All high-performing hospitals had a patient-centered culture, strong follow-up approaches and shared information. Some of these high-quality sites had robust system support while others had creative workarounds (flexibility) or were responsive to their private practice patients. Overall, these pathways had high consistency (.88) and coverage (.72). Only hospitals with both poor follow-up and system support activated the web-based feedback. Conclusions: Safety-net hospitals with poor follow-up capabilities may benefit from an innovation designed to improve hand-offs across specialties. This trial continues to accrue; we are monitoring the innovationâs effectiveness. Clinical trial information: NCT01544374.
- 20 October 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32  (30) , 243
What fixes can improve cancer care quality at safety-net hospitals?
243 Background: Safety-net hospitals are at higher risk of poor quality cancer care and vary in levels of quality performance. Types of quality problems may differ and require different interventions. We undertook this study to identify organizational factors affecting quality and assess the early findings of the innovationâs impact on hand-offs between specialists. Methods: As part of a RCT testing a web-based tracking and feedback innovation to close referral loops, new breast cancer cases are rapidly ascertained, and post-surgical medical and radiation oncologist visits are assessed. Surgeons are alerted to patients who do not show to oncology visits to stimulate action. Of 153 enrolled women (98 Intervention/ 55 Control), 4% are white. In addition, we conducted 90 key informant interviews in 9 safety-net hospitals in the NYC metropolitan area and performed a qualitative comparative analysis (QCA), a method to assess causal complexity, to identify organizational factors associated with poor quality. Results: No-shows at oncology appointments triggering surgeon feedback occurred for 5/98 (5%) new breast cancer patients. QCA revealed 6 conditions associated with poor quality-defined as underuse of needed adjuvant treatment: information sharing; follow-up; system support; patient-centered culture; flexibility and private practice. All high-performing hospitals had a patient-centered culture, strong follow-up approaches and shared information. Some of these high-quality sites had robust system support while others had creative workarounds (flexibility) or were responsive to their private practice patients. Overall, these pathways had high consistency (.88) and coverage (.72). Only hospitals with both poor follow-up and system support activated the web-based feedback. Conclusions: Safety-net hospitals with poor follow-up capabilities may benefit from an innovation designed to improve hand-offs across specialties. This trial continues to accrue; we are monitoring the innovationâs effectiveness. Clinical trial information: NCT01544374.